



ELSEVIER

Contents lists available at ScienceDirect

Diagnostic Microbiology and Infectious Disease

journal homepage: www.elsevier.com/locate/diagmicrobio

Letter to the editor

Commentary re: “Efficacy of a 14-day course of amoxicillin for patients with erythema migrans” by Wormser et al. DMID Jan 2019☆☆



I read with great interest the above noted article by Wormser et al. but am concerned about the assumptions and factual accuracy of the article (Wormser et al., 2019).

In their quest to show the efficacy of a 14-day course of amoxicillin in Lyme disease (LD) the authors' choice of using resolution of erythema migrans (EM) as a primary endpoint and claiming that “erythema migrans (EM) resolved in all patients” is a bit misleading. It is widely known that in the majority of cases of LD the EM rash resolves spontaneously regardless of intervention. Also in this study 2 of 24 developed another episode of EM which could have reflected ongoing illness and should not necessarily be attributed to reinfection as might be assumed (Leigner et al., 1993).

Concluding that a 14-day course of amoxicillin was “highly effective” despite finding that 4 of 24 or 16.7% had post-treatment Lyme disease symptoms (PTLDS) translates into 71,380 cases annually (i.e. 16.7% of 427,430 reported LD cases annually) (Lymedisease.org, n.d.). This is not an insignificant number of affected individuals. In addition, the subjective symptoms of PTLDS including headache, fatigue, brain fog and peripheral neuropathies can be very disabling, and objective biologic evidence supporting their existence is beginning to be demonstrated. A recent study of Coughlin et al. using PET scans found evidence of elevation of a chemical marker indicative of widespread brain inflammation in 12 individuals with documented PTLDS which was absent in 19 healthy controls (Coughlin et al., 2018). Therefore there appears to be evidence of a physiological basis for the “brain fog” that many patients describe. Another study by Novak et al. found that small fiber neuropathy may be responsible for certain sensory symptoms and dysautonomia seen in PTLDS. In addition, the abnormal cerebral blood flow velocity found in the PTLDS individuals studied, may also contribute to the cognitive symptoms observed (Novak et al., 2019).

There are intrinsic limitations in the data presented that do not support the final conclusions. Making firm statements from the small sample size of 24 with a follow-up at 1 year of only 22/24 or 91.7% is easily fraught with errors. Looking only for “objective evidence” of cardiac and neurologic difficulties developing in the first 3 months while doing a 12-month assessment for the development of arthritis to determine primary clinical success is not explained. The medical literature documents that the onset of cardiac or neurologic symptoms can occur months to years after the initial infection.

Closer review of the findings indicate the actual rate of treatment failure in this study is greater than the 16.7% with PTLDS. Only 22/24 were 100% compliant, 4 developed “PTLDS” with 2 more having had recurrent EM. Reanalysis reveals that 6/22 or 27% of the cohort failed treatment. How does a 27% failure rate equate with “highly effective treatment”?

☆ **Funding:** None.

☆☆ **Conflict of Interest:** No conflict of interest to declare.

The authors state that the data presented in this study was taken from 3 ongoing prospective studies. Prospective longer term studies are strongly needed in the area of LD. In the interim, perhaps more caution is required as premature extrapolation of data can risk coming to potentially incorrect conclusions.

Rosalie Greenberg

Medical Arts psychotherapy Associates, PA, 33 Overlook Road
Suite 406, Summit, New Jersey, 07901

Tel.: +1-908-598-0200

E-mail address: rgmd@verizon.net

¹Academic Affiliations: Overlook Hospital, 99 Beauvoir Avenue Summit
New Jersey 07901

<https://doi.org/10.1016/j.diagmicrobio.2019.03.008>

References

- Coughlin JM, Yang T, Rebman AW, Bechtold KT, Du Y, Mathews WB, et al. Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [¹¹C]DPA-713 PET. *J Neuroinflammation* 2018;15(346)<https://doi.org/10.1186/s12974-018-1381-4>.
- Leigner KB, Shapiro JR, Ramsay D, Halperin AJ, Hogrefe W, Kong L. Recurrent erythema migrans despite extended antibiotic treatment with minocycline in a patient with persisting *Borrelia burgdorferi* infection. *J Am Acad Dermatol* 1993;28:312–4. Lymedisease.org.
- Novak P, Felsenstein D, Mao C, Octavien NR, Zubcevic N. Association of small fiber neuropathy and post treatment Lyme disease syndrome. *PLoS One* 2019;14(2), e0212222<https://doi.org/10.1371/journal.pone.0212222>.
- Wormser GP, Brady KC, Cho MS, Scavanda CA, McKenna D. Efficacy of a 14-day course of amoxicillin for patients with erythema migrans. *Diagn Microbiol Infect Dis* 2019<https://doi.org/10.1016/j.diagmicrobio.2019.01.003>. [pii: S0732-8893(18)30330-4. Epub ahead of print].

A 14-day course of amoxicillin is a highly effective treatment for adult patients in the United States with erythema migrans[☆]



We thank Dr. Greenberg for her interest in our study demonstrating that a 14-day course of amoxicillin is highly effective for treating adult patients in the United States with early Lyme disease manifested by the skin lesion erythema migrans (Greenberg, n.d.; Wormser et al., n.d.). Contrary to the assertions of Dr. Greenberg (Greenberg, n.d.), the primary endpoint was *both* the resolution of the erythema migrans skin lesion and the absence of an objective neurologic, cardiac, or rheumatologic manifestation of Lyme disease (Wormser et al., n.d.). The natural history of untreated patients with erythema migrans is remarkably different from that which we observed. In untreated patients, over 50% will develop joint swelling from Lyme arthritis within 12 months, approximately 11% will develop an objective neurologic manifestation within 3 months, and approximately 4% will develop objective evidence of Lyme carditis within 3 months (Steere et al., 1980, 1987). None of our patients developed any of these complications over the entire

study period. In our study, the final assessment occurred at or after 9 months for all of the study subjects and at or after 12 months for 91.7% of the subjects (Wormser et al., n.d.). Also, contrary to Dr. Greenberg's assertions, in the United States, there is no evidence of late-onset cardiac manifestations of Lyme disease. Although late-onset neurologic manifestations of Lyme disease have been reported, these conditions are highly controversial and are extremely rare, if they occur at all in the United States (Wormser et al., 2006, 2017).

In our study, the first follow-up visit occurred at a mean of 14 days after the baseline visit (range 5–31 days), allowing us to document for all of our patients that the erythema migrans was either fully resolved or had substantially improved by this time point. In contrast to untreated patients (Steere et al., 1980), in our patients, there was no expansion of the skin lesion after the first 24 h of treatment, and none developed additional erythema migrans skin lesions prior to the next Lyme disease season. Two of the 24 patients in our study had a second episode of erythema migrans at a different skin site during the following summer. As we have clearly demonstrated in a prior study (Nadelman et al., 2012), such recurrences of erythema migrans occur as a result of reinfections, *not* from relapses of the original infection. This was established by genetic analyses of the isolates of *Borrelia burgdorferi* recovered on culture from each episode of erythema migrans, by which it was demonstrated that subsequent episodes of erythema migrans are caused by a different strain of *B. burgdorferi* (Nadelman et al., 2012). The 2 patients with a recurrence of erythema migrans in our amoxicillin treatment study similarly were infected with a strain of *B. burgdorferi* in the subsequent episode that was genetically different from the strain that caused the episode present at the time of study entry.

Although 4 of our patients (16.7%) had residual subjective symptoms following treatment, this figure is quite consistent with the results of 8 other treatment trials in the United States, irrespective of the antibiotic regimen prescribed, in which the frequency of such symptoms has ranged from 0% to 40.8% (median 11.5%) (Cerar et al., 2010). It is important to recognize that there is a distinction between posttreatment Lyme disease symptoms and the condition referred to as posttreatment Lyme disease syndrome since only the latter is characterized by functional disability (Wormser et al., 2006). Although the frequency of post-Lyme disease syndrome has usually not been reported in treatment trials of patients with erythema migrans, evidence from the 4 reported National Institutes of Health-sponsored antibiotic retreatment trials of Lyme disease patients with posttreatment functional disability suggests that this condition is actually very uncommon, as all of the trials experienced difficulties in recruiting a sufficient number of eligible study subjects (Klempner et al., 2013). Of the 5457 individuals screened for these trials, only 221 (4.0%) were randomized over recruitment periods of 2.6 to 4.3 years (Klempner et al., 2013). Of note, at least 40% of the potential study subjects were excluded due to lack of evidence of previous Lyme disease (Klempner et al., 2013).

In our study, none of the subjects had any objective evidence of treatment failure, the vast majority were 100% compliant with taking the 3 times per day dosing of amoxicillin, and all of the patients were closely and systematically followed for an appropriate duration of time to assess outcome (Wormser et al., n.d.). Similar to the findings of several studies conducted in Europe (Arnez and Ruzic-Sabljić, 2015; Eliassen et al., 2017, 2018; Nizic et al., 2012), the data from our study demonstrate that a 14-day course of amoxicillin is highly effective treatment for patients with erythema migrans in the United States (Wormser et al., n.d.).

Acknowledgments

The authors thank Lisa Giarratano for assistance.

Funding

RO1 CK 000152 from the Centers for Disease Control and Prevention (CDC) to G.P.W. The findings and conclusions of this paper are those of the authors and do not necessarily represent the official position of the CDC.

Disclosures

Dr. Wormser reports receiving research grants from Immunetics, Inc.; Institute for Systems Biology; Rarecyte, Inc.; and Quidel Corporation. He owns equity in Abbott/AbbVie, has been an expert witness in malpractice cases involving Lyme disease, and is an unpaid board member of the American Lyme Disease Foundation. The other authors have no disclosures.

Gary P. Wormser*
Kathryn C. Brady
Michelle S. Cho
Carol A. Scavarda
Donna McKenna

Division of Infectious Diseases, New York Medical College
Valhalla, NY 10595

*Corresponding author. Tel.: +1-914-493-8865; fax: +1-914-493-7289

E-mail address: gwormser@nymc.edu

<https://doi.org/10.1016/j.diagmicrobio.2019.03.009>

References

- Arnez M, Ruzic-Sabljić E. Azithromycin is equally effective as amoxicillin in children with solitary erythema migrans. *Pediatr Infect Dis J* 2015;34:1045–8.
- Cerar D, Cerar T, Ruzic-Sabljić E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. *Am J Med* 2010;123:79–86.
- Eliassen KE, Hjetland R, Reiso H, Lindbaek M, Tschudi-Madsen H. Symptom load and general function among patients with erythema migrans: a prospective study with a one year follow-up after antibiotic treatment in Norwegian general practice. *Scand J Prim Health Care* 2017;35:75–83.
- Eliassen KE, Reiso H, Berold D, Lindbaek M. Comparison of phenoxymethyl penicillin, amoxicillin, and doxycycline for erythema migrans in general practice. a randomized controlled trial with a one year follow-up. *Clin Microbiol Infect* 2018 <https://doi.org/10.1016/j.cmi.2018.02.028>. [pii: S1198-743x (18) 30203-9].
- Greenberg R. Commentary re: "Efficacy of a 14-day course of amoxicillin for patients with erythema migrans" *Diagn Microbiol Infect Dis.*; 2019.
- Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ, et al. Treatment trials for post-Lyme disease symptoms revisited. *Am J Med* 2013;126:665–9.
- Nadelman RB, Hanincova K, Mukherjee P, Liveris D, Nowakowski J, McKenna D, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. *N Engl J Med* 2012;367:1883–90.
- Nizic T, Velikanje E, Ruzic-Sabljić E, Arnez M. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. *Wien Klin Wochenschr* 2012;124:427–33.
- Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH. Antibiotic therapy in Lyme disease. *Ann Intern Med* 1980;93(part 1):1–8.
- Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. *Ann Intern Med* 1987;107:725–31.
- Wormser GP, Brady KC, Cho MS, Scavarda CA, McKenna D. Efficacy of a 14-day course of amoxicillin for patients with erythema migrans. *Diagn Microbiol Infect Dis* [Epub ahead of print] 2019.
- Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006;43:1089–134.
- Wormser GP, Strle F, Shapiro ED, Dattwyler RJ, Auwaerter PG. A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease. *Diagn Microbiol Infect Dis* 2017;87:163–7.